Immunovant Secures $994.5M Cash, Advances IMVT-1402 Trials, Shares Up 17%
Immunovant shares have climbed 17% in three months, driven by enrollment completion in the D2T-RA trial and scheduled IMVT-1402 top-line data in H2 2026 and 2027. The company holds $994.5 million in cash after a $550 million financing, funding its pipeline through potential GD product launch.
1. Share Performance
Immunovant shares have risen 17% over the past three months and roughly 40% over the last year, outpacing the industry’s 14.7% growth and reflecting heightened investor confidence in its development milestones.
2. Pipeline Milestones
Enrollment has been completed in the open-label portion of the IMVT-1402 D2T-RA trial, with top-line results due in the second half of 2026. Registrational trials for Graves’ disease and myasthenia gravis are slated for 2027 data readouts, while a proof-of-concept study in cutaneous lupus erythematosus is expected in H2 2026. Separately, batoclimab’s late-stage data for thyroid eye disease are anticipated in the first half of 2026.
3. Financial Position
In December 2025, Immunovant raised $550 million through an underwritten financing, boosting its cash and equivalents to $994.5 million as of December 31, 2025. This substantial liquidity supports ongoing clinical programs and extends the runway toward a potential commercial launch of IMVT-1402 in Graves’ disease.